Mouse methylome studies SRP503857 Track Settings
 
Mutant IDH1 inhibition induces reverse transcriptase and dsDNA sensing to activate tumor immunity [mouse WGBS] [Cholangiocarcinoma, Liver]

Track collection: Mouse methylome studies

+  All tracks in this collection (596)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG methylation ▾       HMR       CpG reads ▾       PMD      
Select subtracks by views and experiment:
 All views AMR  CpG methylation  HMR  CpG reads  PMD 
experiment
SRX24360763 
SRX24360764 
SRX24360765 
SRX24360766 
SRX24360767 
SRX24360768 
SRX24360769 
SRX24360770 
SRX24360771 
SRX24360772 
SRX24360773 
SRX24360774 
SRX24360775 
SRX24360776 
SRX24360777 
SRX24360778 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX24360763  CpG methylation  Cholangiocarcinoma / SRX24360763 (CpG methylation)   Schema 
hide
 SRX24360775  HMR  Liver / SRX24360775 (HMR)   Schema 
hide
 Configure
 SRX24360764  CpG methylation  Cholangiocarcinoma / SRX24360764 (CpG methylation)   Schema 
hide
 SRX24360776  HMR  Liver / SRX24360776 (HMR)   Schema 
hide
 Configure
 SRX24360765  CpG methylation  Cholangiocarcinoma / SRX24360765 (CpG methylation)   Schema 
hide
 SRX24360777  HMR  Liver / SRX24360777 (HMR)   Schema 
hide
 SRX24360778  HMR  Liver / SRX24360778 (HMR)   Schema 
hide
 Configure
 SRX24360766  CpG methylation  Cholangiocarcinoma / SRX24360766 (CpG methylation)   Schema 
hide
 Configure
 SRX24360767  CpG methylation  Cholangiocarcinoma / SRX24360767 (CpG methylation)   Schema 
hide
 Configure
 SRX24360768  CpG methylation  Cholangiocarcinoma / SRX24360768 (CpG methylation)   Schema 
hide
 Configure
 SRX24360769  CpG methylation  Cholangiocarcinoma / SRX24360769 (CpG methylation)   Schema 
hide
 Configure
 SRX24360770  CpG methylation  Cholangiocarcinoma / SRX24360770 (CpG methylation)   Schema 
hide
 Configure
 SRX24360771  CpG methylation  Cholangiocarcinoma / SRX24360771 (CpG methylation)   Schema 
hide
 Configure
 SRX24360772  CpG methylation  Cholangiocarcinoma / SRX24360772 (CpG methylation)   Schema 
hide
 Configure
 SRX24360773  CpG methylation  Cholangiocarcinoma / SRX24360773 (CpG methylation)   Schema 
hide
 Configure
 SRX24360774  CpG methylation  Cholangiocarcinoma / SRX24360774 (CpG methylation)   Schema 
hide
 Configure
 SRX24360775  CpG methylation  Liver / SRX24360775 (CpG methylation)   Schema 
hide
 Configure
 SRX24360776  CpG methylation  Liver / SRX24360776 (CpG methylation)   Schema 
hide
 Configure
 SRX24360777  CpG methylation  Liver / SRX24360777 (CpG methylation)   Schema 
hide
 Configure
 SRX24360778  CpG methylation  Liver / SRX24360778 (CpG methylation)   Schema 
    

Study title: Mutant IDH1 inhibition induces reverse transcriptase and dsDNA sensing to activate tumor immunity [mouse WGBS]
SRA: SRP503857
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX24360763 Cholangiocarcinoma 0.530 15.4 54868 13563.7 414 998.5 2636 504533.8 0.983 title: GSM8229476 WGBS, 2205 in vitro, DMSO, Replicate 1, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: DMSO; geo_loc_name: missing; collection_date: missing
SRX24360764 Cholangiocarcinoma 0.525 12.9 47717 14688.2 346 1011.4 2083 635888.9 0.986 title: GSM8229477 WGBS, 2205 in vitro, DMSO, Replicate 2, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: DMSO; geo_loc_name: missing; collection_date: missing
SRX24360765 Cholangiocarcinoma 0.525 11.6 44091 15401.9 302 1002.8 2089 632726.6 0.985 title: GSM8229478 WGBS, 2205 in vitro, DMSO, Replicate 3, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: DMSO; geo_loc_name: missing; collection_date: missing
SRX24360766 Cholangiocarcinoma 0.531 12.7 48109 14631.4 361 1003.2 2102 630913.7 0.986 title: GSM8229479 WGBS, 2205 in vitro, IFNg, Replicate 1, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: IFN; geo_loc_name: missing; collection_date: missing
SRX24360767 Cholangiocarcinoma 0.527 11.5 44841 15257.0 287 1062.9 2079 636608.8 0.986 title: GSM8229480 WGBS, 2205 in vitro, IFNg, Replicate 2, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: IFN; geo_loc_name: missing; collection_date: missing
SRX24360768 Cholangiocarcinoma 0.526 11.8 44410 15271.1 308 1025.2 2094 633501.8 0.985 title: GSM8229481 WGBS, 2205 in vitro, IFNg, Replicate 3, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: IFN; geo_loc_name: missing; collection_date: missing
SRX24360769 Cholangiocarcinoma 0.334 10.5 33217 16431.4 28944 1270.7 1998 571875.4 0.985 title: GSM8229482 WGBS, 2205 in vitro, AG120, Replicate 1, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: AG120; geo_loc_name: missing; collection_date: missing
SRX24360770 Cholangiocarcinoma 0.333 11.1 35345 15809.0 34962 1320.6 2040 560718.2 0.984 title: GSM8229483 WGBS, 2205 in vitro, AG120, Replicate 2, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: AG120; geo_loc_name: missing; collection_date: missing
SRX24360771 Cholangiocarcinoma 0.329 12.3 37672 15104.1 40619 1341.7 2814 397432.4 0.984 title: GSM8229484 WGBS, 2205 in vitro, AG120, Replicate 3, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: AG120; geo_loc_name: missing; collection_date: missing
SRX24360772 Cholangiocarcinoma 0.330 10.7 33911 16305.2 18101 1238.1 2095 543873.4 0.985 title: GSM8229485 WGBS, 2205 in vitro, AG120+IFNg, Replicate 1, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: AG120 + IFN; geo_loc_name: missing; collection_date: missing
SRX24360773 Cholangiocarcinoma 0.325 11.2 35019 15905.2 21325 1239.9 2122 535741.7 0.984 title: GSM8229486 WGBS, 2205 in vitro, AG120+IFNg, Replicate 2, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: AG120 + IFN; geo_loc_name: missing; collection_date: missing
SRX24360774 Cholangiocarcinoma 0.327 12.0 37057 15333.1 23305 1251.2 2083 544752.9 0.984 title: GSM8229487 WGBS, 2205 in vitro, AG120+IFNg, Replicate 3, Mus musculus, Bisulfite-Seq; source_name: cholangiocarcinoma; tissue: cholangiocarcinoma; cell_line: 2205; cell_type: tumor cells; genotype: Albumin-Cre, KrasG12D, IDH1R132C; treatment: AG120 + IFN; geo_loc_name: missing; collection_date: missing
SRX24360775 Liver 0.724 11.3 41923 1253.5 641 937.8 1502 14213.7 0.983 title: GSM8229488 WGBS, normal liver, Vehicle, Replicate 1, Mus musculus, Bisulfite-Seq; source_name: liver; tissue: liver; cell_type: liver cells; genotype: Wildtype; treatment: Vehicle; geo_loc_name: missing; collection_date: missing
SRX24360776 Liver 0.724 11.2 41582 1255.1 664 915.6 1436 14297.2 0.984 title: GSM8229489 WGBS, normal liver, Vehicle, Replicate 2, Mus musculus, Bisulfite-Seq; source_name: liver; tissue: liver; cell_type: liver cells; genotype: Wildtype; treatment: Vehicle; geo_loc_name: missing; collection_date: missing
SRX24360777 Liver 0.725 11.3 42055 1250.1 599 930.9 1481 14403.8 0.984 title: GSM8229490 WGBS, normal liver, AG120, Replicate 1, Mus musculus, Bisulfite-Seq; source_name: liver; tissue: liver; cell_type: liver cells; genotype: Wildtype; treatment: AG120; geo_loc_name: missing; collection_date: missing
SRX24360778 Liver 0.730 11.9 42151 1251.4 707 872.7 1468 14639.4 0.985 title: GSM8229491 WGBS, normal liver, AG120, Replicate 2, Mus musculus, Bisulfite-Seq; source_name: liver; tissue: liver; cell_type: liver cells; genotype: Wildtype; treatment: AG120; geo_loc_name: missing; collection_date: missing

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.